CTOs on the Move

Crosscart Inc

www.crosscart.com

 
Crosscart Inc is a San Francisco, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 25-100
  • Annual Revenue: $10-50 Million
  • www.crosscart.com
  • 3727 Buchanan St Ste 203
    San Francisco, CA USA 94123
  • Phone: 415.923.6444

Executives

Name Title Contact Details

Similar Companies

Molecular Express

Molecular Express is a Rancho Dominguez, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Terumo Heart

Terumo Heart, Inc. is a Ann Arbor, MI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

hhoaltd

hhoaltd is a Hinsdale, IL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Surrozen

Surrozen is discovering and developing novel regenerative medicines with a focus on unlocking the powerful self-renewal properties of the body through specific control of the Wnt signaling pathway. The Wnt pathway plays a critical role in stem cell maintenance, tissue regeneration and other important developmental processes. Abnormalities in the Wnt pathway have been linked to many human diseases, revealing a powerful underlying biology with relevance to a broad spectrum of organs and tissues. Surrozen is implementing a platform of `surrogate` Wnt molecules to selectively activate the Wnt pathway for the treatment of injury and disease—overcoming key hurdles that have held back industry-wide drug development efforts in this promising area of biology. Surrozen is founded by four leading edge scientists from Stanford University: K. Christopher Garcia, Ph.D. Roel Nusse, Ph.D. Calvin Kuo, M.D., Ph.D.; and Claudia Janda, Ph.D. Each has conducted extensive research on Wnt signaling, with findings that together shape Surrozen`s technology and approach to therapeutic development.

ZS Pharma

ZS Pharma is using innovative technology to change the landscape of disease management. At ZS Pharma, we have a vision—to transform the status quo and improve the options for patients and physicians facing difficult-to-manage conditions such as ion imbalances. We are committed to taking on medicine’s challenges with a new outlook, and we believe that real progress comes with a real promise to approach things in a novel way.